Indivior lifts revenue guidance, cuts profit outlook after Opiant deal
Sharecast
Published Apr 27, 2023 15:41
Indivior lifts revenue guidance, cuts profit outlook after Opiant deal
Sharecast - In the quarter to the end of March, pre-tax profit rose to $58m from $48m in the same period a year earlier, while adjusted operating profit was up 31% at $71m. Net revenue ticked up 22% to $253m.
Net revenue for Sublocade was 55% higher at $132m. Indivior (LON:INDV) said this reflects strong growth in the Organized Health Systems (OHS) channel and continued new US patient enrolments. Meanwhile, net revenue for Perseris extended-release injection rose 60% on the first quarter of 2022 to $8m.
The company lifted its full-year net revenue guidance to between $970m and $1.04bn, from previous guidance of $950m to $1.02bn. However, its outlook for adjusted operating profit was reduced to "slightly below" FY 2022's adjusted operating income of $212m, as a result of the additional operating expenses associated with the Opiant acquisition.
Previously, Indivior had said that adjusted operating profit would be higher than in 2022.
Chief executive Mark Crossley said: "Sublocade (buprenorphine extended-release) injection continues to power our growth as we drive greater depth of prescribing across Organized Health Systems (OHS) in the treatment of moderate-to-severe opioid use disorder (OUD).
"Within the quarter, we also completed the acquisition of Opiant Pharmaceuticals, Inc. This important strategic step strengthens our addiction portfolio through the addition of OPNT003 (nalmefene nasal spray), a new potential option for opioid overdose reversal which we expect to launch in the US in the fourth quarter, subject to regulatory approval."
At 1435 BST, the shares were up 3.1% at 1,516p.
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.